sulfadiazine   Click here for help

GtoPdb Ligand ID: 12635

Approved drug
sulfadiazine is an approved drug (FDA (1941), UK (2008))
Compound class: Synthetic organic
Comment: Sulfadiazine is a sulfonamide with broad-spectrum antimicrobial activity [4]. It is used in the treatment of toxoplasmosis, an infection with the protozoan parasite Toxoplasma gondi that can cause serious complications during pregnancy and in patients with weakened immune systems. Dermatological formulations containing silver sulfadiazine (PubChem CID 441244) are used to prevent and treat wound infections.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 3
Topological polar surface area 105.29
Molecular weight 250.28
XLogP -1.47
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1=CN=C(N=C1)NS(=O)(=O)C2=CC=C(C=C2)N
Isomeric SMILES C1=CN=C(N=C1)NS(=O)(=O)C2=CC=C(C=C2)N
InChI InChI=1S/C10H10N4O2S/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10/h1-7H,11H2,(H,12,13,14)
InChI Key SEEPANYCNGTZFQ-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Sulfadiazine is listed in the World Health Organisation's EML for use in the treatment of toxoplasmosis. The EML also includes silver sulfadiazine as an anti-infective medicine for topical use. Sulfadiazine is approved by the US FDA and is also authorised for use in the UK. The drug is not approved by the EMA, but individual European agencies have authorised its use.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Sulfonamides are structural analogues of 4-aminobenzoic acid (pABA) an intermediate in the de novo synthesis of folate by some prokaryotes, lower eukaryotes and plants [2]. The antibacterial MMOA is competitive inhibition of bacterial dihydropteroate synthase (DHPS) resulting in a block of folate biosynthesis [1].
External links Click here for help